[go: up one dir, main page]

MX2020011742A - Métodos de tratamiento con compuestos metálicos mixtos. - Google Patents

Métodos de tratamiento con compuestos metálicos mixtos.

Info

Publication number
MX2020011742A
MX2020011742A MX2020011742A MX2020011742A MX2020011742A MX 2020011742 A MX2020011742 A MX 2020011742A MX 2020011742 A MX2020011742 A MX 2020011742A MX 2020011742 A MX2020011742 A MX 2020011742A MX 2020011742 A MX2020011742 A MX 2020011742A
Authority
MX
Mexico
Prior art keywords
mixed metal
treatment
methods
metal compounds
subject
Prior art date
Application number
MX2020011742A
Other languages
English (en)
Inventor
P Martin Petkovich
Original Assignee
Eirgen Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eirgen Pharma Ltd filed Critical Eirgen Pharma Ltd
Publication of MX2020011742A publication Critical patent/MX2020011742A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un método para tratar y/o prevenir calcificación vascular puede incluir administrar un compuesto metálico mixto a un sujeto en necesidad del mismo.
MX2020011742A 2018-10-25 2019-10-25 Métodos de tratamiento con compuestos metálicos mixtos. MX2020011742A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862750791P 2018-10-25 2018-10-25
PCT/IB2019/001149 WO2020084349A1 (en) 2018-10-25 2019-10-25 Methods of treatment with mixed metal compounds

Publications (1)

Publication Number Publication Date
MX2020011742A true MX2020011742A (es) 2021-02-15

Family

ID=68732014

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011742A MX2020011742A (es) 2018-10-25 2019-10-25 Métodos de tratamiento con compuestos metálicos mixtos.

Country Status (12)

Country Link
US (1) US20200129545A1 (es)
EP (1) EP3873490A1 (es)
JP (1) JP2022509447A (es)
KR (1) KR20210091185A (es)
CN (1) CN113164515A (es)
AU (1) AU2019363816A1 (es)
BR (1) BR112021007757A2 (es)
CA (1) CA3116635A1 (es)
EA (1) EA202191134A1 (es)
IL (1) IL282293A (es)
MX (1) MX2020011742A (es)
WO (1) WO2020084349A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115227832B (zh) * 2022-07-13 2025-08-22 南方医科大学 植物来源纳米颗粒在制备防治血管钙化药物中的应用
WO2025094144A1 (en) 2023-11-02 2025-05-08 Eirgen Pharma Ltd. Controlling loss of kidney function

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720061D0 (en) 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
US20040226620A1 (en) 2002-09-26 2004-11-18 Daniel Therriault Microcapillary networks
US7664834B2 (en) 2004-07-09 2010-02-16 Maxsp Corporation Distributed operating system management
GB0502787D0 (en) 2005-02-10 2005-03-16 Ineos Silicas Ltd Pharmaceuticlly active compounds, their manufacture, compositions containing them and their use
JP2008533170A (ja) * 2005-03-17 2008-08-21 アムジエン・インコーポレーテツド 石灰化減少方法
MY157620A (en) 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
GB0714670D0 (en) 2007-07-27 2007-09-05 Ineos Healthcare Ltd Use
GB0720220D0 (en) * 2007-10-16 2007-11-28 Ineos Healthcare Ltd Compound
GB0913525D0 (en) 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
GB201001779D0 (en) * 2010-02-04 2010-03-24 Ineos Healthcare Ltd Composition
KR102287207B1 (ko) * 2013-04-12 2021-08-09 알데릭스, 인코포레이티드 Nhe3-결합 화합물 및 포스페이트 수송을 저해하는 방법

Also Published As

Publication number Publication date
BR112021007757A2 (pt) 2021-07-27
AU2019363816A1 (en) 2021-05-13
EP3873490A1 (en) 2021-09-08
EA202191134A1 (ru) 2021-07-13
CA3116635A1 (en) 2020-04-30
IL282293A (en) 2021-05-31
CN113164515A (zh) 2021-07-23
KR20210091185A (ko) 2021-07-21
JP2022509447A (ja) 2022-01-20
US20200129545A1 (en) 2020-04-30
WO2020084349A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
PH12019502132A1 (en) Combination therapy for the treatment or prevention of tumours
MX2025000380A (es) Metodos de tratamiento con farmacos del sustrato cyp3a4
MX2021004821A (es) Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
MX2022010270A (es) Nuevo enfoque para tratar el cancer mediante el uso de la inmunomodulacion.
MX2020008906A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso de estos.
MX2020011653A (es) Métodos de tratamiento para el abuso de sustancias.
MX2022008868A (es) Tratamiento del cancer con tg02.
MY208231A (en) Mavacamten for use in the treatment of hypertrophic cardiomyopathy
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
MY201148A (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
MX2021005646A (es) Métodos de tratamiento de cáncer con agentes de unión a tubulina.
MY192055A (en) Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation
SG10201810401RA (en) Pharmaceutical combinations for treating cancer
MX2023002323A (es) Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2020006224A (es) Metodos y terapia combinada para el tratamiento del cancer.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX365366B (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
MX2020011742A (es) Métodos de tratamiento con compuestos metálicos mixtos.
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2022002751A (es) Tratamiento de la abstinencia de opioides.
MX2020001164A (es) Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico.
MY197563A (en) Kimchi for preventing or treating helicobacter pylori-associated diseases
MX2021003160A (es) Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama.
MX2019004804A (es) Tratamiento para el prurigo nodula.